Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $10.03 Analyst target: $31.50 Upside: 214.06%
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.
See the full interactive analysis & chart →Informational only — not investment advice.